Transcode Therapeutics, Inc.
Doing business as Transcode
- UEI
- M4SWK8BE2J85
- CAGE
- 7PCT5
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- transcodetherapeutics.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Phase i clinical testing of a first-in-class therapy against metastatic cancer - summary metastatic disease is… | National Cancer Institute | $1,999,972 | |
| Clinical development of first-in-class therapy for metastatic breast cancer - we have developed a new therapeutic… | National Cancer Institute | $5,185,215 |
Quick answers
What is Transcode Therapeutics, Inc.'s UEI?
Transcode Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is M4SWK8BE2J85.
What is Transcode Therapeutics, Inc.'s CAGE code?
Transcode Therapeutics, Inc.'s CAGE code is 7PCT5.
Is Transcode Therapeutics, Inc. registered in SAM.gov?
Transcode Therapeutics, Inc.'s SAM.gov registration expired on September 29, 2026.
What is Transcode Therapeutics, Inc.'s most recent federal award?
Transcode Therapeutics, Inc.'s most recent federal grant award is Phase i clinical testing of a first-in-class therapy against metastatic cancer - summary metastatic disease is… (R44CA295173), from National Cancer Institute, on September 4, 2024.
On GovTribe
See Transcode Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors